A closer look
The mask of pharmaceutical altruism slipped beautifully in a 2018 Goldman Sachs biotech research report. Financial analysts openly pondered whether providing one-shot cures for diseases was a 'sustainable business model' for investors, clinically noting that a cured patient is a lost customer. Late-stage capitalism quite literally prefers keeping you chronically ill on an expensive subscription plan rather than actually fixing you.






